AMRN's obstacle to selling Vascepa isn't that the company's too small its that their strategy is poor and that their spokesman is the worst guy on earth IMHO (not Bhatt of course Bhatt is fine I mean JT).
I'd favor GIA if I had confidence in the management but it is very clear that between JT's magical ability to put people to sleep and his poor decisions regarding marketing strategy that we'll be waiting till the patents expire before Vascepa gets the kind of market penetration it deserves...
In view of that I would prefer if he sold the company even though I think with the right CEO it'd be worth 1000 soon with him it won't even get to 40 a year from now. I guess its great to sell call options on knowing that you will never have to regret it.
News 
Market Data 
Discover 
AI
